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Prurigo Nodularis
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Case RepoRt
A 72-year-old Danish man, who had lived in Ilulissat in the 
Avannaa district in the North-western part of Greenland for 
almost 30 years, consulted the local hospital. He presented 
with multiple, extremely pruritic, symmetrically distributed, 
excoriated, lichenified papules on the trunk and especially on 
the lower extremities (Fig. 1).
A punch biopsy of a lichenified noduli on the lower right 
leg was sent to Denmark. A pathologist found an acanthotic 
epidermis with mild spongiosis and dermis, containing a 
scattered mononuclear infiltrate with slight fibrosis, consistent 
with lichen simplex chronicus. 
Clinically, our patient’s skin lesions were classical prurigo nod-
ularis (PN). The therapeutic course over several years included 
high-potency topical steroids, intralesional triamcinolone 10 
mg/ml, oral antihistamines, and systemic prednisone. The 
patient achieved no clearance of lesions or any symptomatic 
relief by any of the above-mentioned treatment modalities. 
Since the patient lived in Ilulissat in Greenland broad-banded 
ultraviolet B phototherapy was not an available treatment 
option and the patient was not a candidate for either metho-
trexate or cyclosporine due to his impaired liver and renal 
function. 
Treatment of PN is challenging. Consequently, patients often 
endure multiple unsuccessful therapeutic trials. Especially 
in Greenland it can be challenging to treat patients with 
relatively rare dermatologic diseases because of the limited 
dermatologic service in the area. Sometimes there are even 
difficulties in getting a proper diagnosis via the existing 
teledermatological services. 
DisCussion
PN is a rare and chronic dermatologic condition featured by 
multiple intensely itchy, excoriated hyperkeratotic nodules on 
the extensor surfaces of the arms and legs and on the trunk, 
with a symmetrical distribution (1). 
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The disorder can be associated with multiple systemic condi-
tions, including neuropathies, chronic kidney disease, type 
2 diabetes, atopic dermatitis and human immunodeficiency 
virus infection (1, 2). For most patients, multiple underlying 
causes can be identified. The intense pruritus is often associ-
ated with disturbed sleep and reduced quality of life. Anxiety, 
depression and even suicide in patients with PN have been 
reported (3, 4).
A large German study examined 108 patients with PN in a 
predominantly Caucasian population and observed a female 
predominance (64%) with a median age of onset at 61.5 
years (5). 
Repetitive itching on the skin may start a cascade of processes 
in the skin involving the immune system, neurons and epi-
thelial cells, causing an urge to repeated scratching, known 
as the itch-scratch cycle. Many theories about the pathogen-
esis of PN have been hypothesized, including growth of the 
peripheral nerves leading to hypersensitivity of the nerve 
endings and increased levels of substance P in the small nerve 
fibres in dermis. 
Recent studies on the pathogenetic mechanisms of PN have 
revealed the importance of pro-inflammatory cytokines, such 
as IL-31, and neuropeptides in skin lesions that may contrib-
ute to altered nerve density and increased inflammation in 
PN (6–8). Despite the tremendous burden of disease of PN 
there is surprisingly little known about the aetiology and 
epidemiology of it.
Recent studies have studied intraepidermal nerve fibre density 
(IENFD) as an important contributor to chronic pruritus and 
small fibre neuropathies (9,10). Patients with PN decreased 
IENFD compared to healthy individuals (9). Furthermore, there 
is a significant reduction in IENFD in PN skin lesions, which 
may be due to prolonged scratching, but also in non-lesional 
PN. Indeed, the resolution of pruritus is associated with the 
recovery of dermal nerve fibre density (10). 
For dermatologists, the management of PN is challenging due 
to the lack of a fundamental understanding of the disease, 
combined with limited treatment options. 
tReatment
The approach to treating PN is always multifaceted. A strategy 
of treatment includes both a pharmacological and a non-phar-
macological part. Patient education on how to disrupt the 
itch–scratch cycle is essential. The general advice here is to 
keep the nails short, wear protective clothes (long sleeves 
and gloves), and keep the nodules covered with bandages or 
dressings. Patients are to be encouraged to apply emollients 
multiple times a day and only use gentle cleansers when 
showering. To reduce pruritus one can try calamine lotions 
and lotions containing menthol and camphor. Other recom-
mendations are to stay in a cool comfortable environment 
and reduce stress. 
The pharmacological treatments used to treat PN are multiple 
but there is only limited data from randomized controlled 
trials available. The consensus of treating PN is a stepwise 
treatment approach (11, 12). First step includes the use of 
potent topical corticosteroids and topical calcineurin inhib-
itors. The topical corticosteroids are often used under occlu-
sive dressings to increase efficacy. If only a relatively small 
number of PN elements are present, intralesional injections 
of corticosteroids or cryotherapy are effective options in the 
early treatment strategy. UV phototherapy have been widely 
used but with mixed results, usually as narrowband UVB and 
bath PUVA (psoralen and UVA). 
The next step in topical treatment is the use of a cream 
containing the chili pepper extract capsaicin. Physicians 
prescribing this cream must be aware that increased itch is 
a common side effect. If topical treatments are not effective, 
systemic treatments are the next step, both on their own and 
in combination with topical treatments. A number of systemic 
treatments with different modes of action have been used in 
treating PN. Gabapentinoids are usually the first steps of sys-
temic treatment. Their modes of action are poorly understood, 
but seem to reduce the symptoms by inhibiting descending 
serotonergic facilitation. The use of antidepressants (SSRIs), 
as next step substantiates that serotonin is part of the patho-
genesis of PN. In the treatment strategy of PN the use of 
immunosuppressants are the next level of pharmaceuticals 
to prescribe. Amongst immunosuppressants, cyclosporine and 
methotrexate are most commonly used. 
In recent time we have seen more studies showing promising 
results in treating this burdensome disease. Ständer et al. (13) 
showed clinically meaningful itch reduction after treating with 
Serlopitant, a neurokinin-1-inhibitor. Other ongoing trials 
with promising drugs have been reported to reduce itch in 
PN. Worth mentioning here are the interleukin-4-receptor A 
antibody dupilumab and the anti-IL-31 receptor-A antibody 
nemolizumab. With these targeted drugs we will hopefully get 
new powerful tools to treat recalcitrant cases of PN.
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